DURECT Stock (NASDAQ:DRRX)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$1.32

52W Range

$0.47 - $2.89

50D Avg

$1.39

200D Avg

$1.23

Market Cap

$41.59M

Avg Vol (3M)

$61.57K

Beta

1.13

Div Yield

-

DRRX Company Profile


DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine up to days of in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Santen Pharmaceutical Co., Ltd. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

48

IPO Date

Sep 28, 2000

Website

DRRX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 20
Product$6.27M$6.08M$6.17M
Collaborative Research And Development And Other Revenue$2.28M--

Fiscal year ends in Dec 23 | Currency in USD

DRRX Financial Summary


Dec 23Dec 22Dec 21
Revenue$8.55M$19.28M$13.98M
Operating Income$-36.88M$-35.08M$-34.27M
Net Income$-27.62M$-35.58M$-38.13M
EBITDA$-36.88M$-32.93M$-34.12M
Basic EPS$-1.05$-1.56$-1.69
Diluted EPS$-1.05$-1.56$-1.69

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 13, 24 | 8:42 PM
Q1 24May 13, 24 | 12:00 AM
Q4 23Mar 27, 24 | 6:07 PM

Peer Comparison


TickerCompany
SNOASonoma Pharmaceuticals, Inc.
RDHLRedHill Biopharma Ltd.
EVOKEvoke Pharma, Inc.
TKNOAlpha Teknova, Inc.
AQSTAquestive Therapeutics, Inc.
LFCRLifecore Biomedical, Inc.
ORGOOrganogenesis Holdings Inc.
GHSIGuardion Health Sciences, Inc.
NBIXNeurocrine Biosciences, Inc.
IRWDIronwood Pharmaceuticals, Inc.
ALIMAlimera Sciences, Inc.
SHPHShuttle Pharmaceuticals Holdings, Inc.
ACRXTalphera, Inc.
DCPHDeciphera Pharmaceuticals, Inc.
ADMPAdamis Pharmaceuticals Corporation
LSDILucy Scientific Discovery Inc.
AGRXAgile Therapeutics, Inc.
ALKSAlkermes plc
COLLCollegium Pharmaceutical, Inc.
AVDLAvadel Pharmaceuticals plc
EGRXEagle Pharmaceuticals, Inc.